SCHEMBL159571

SCHEMBL159571

Nc1ccc(Br)c(Cl)c1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 1/20 0.33
AXL P30530 1/20 0.32
ALDH1A1 P00352 6/20 0.32
CYP3A4 P08684 3/20 0.32
TSHR P16473 3/20 0.32
TDP1 Q9NUW8 2/20 0.32
ALOX15 P16050 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MEN1 O00255 3/20 0.31
MAPT P10636 3/20 0.31
KMT2A Q03164 3/20 0.31
KDM1A O60341 2/20 0.31
KCNH2 Q12809 2/20 0.31
KDM1B Q8NB78 2/20 0.31
POLB P06746 2/20 0.31
L3MBTL1 Q9Y468 2/20 0.31
HTT P42858 1/20 0.31
NPC1 O15118 1/20 0.31
THRB P10828 1/20 0.31
APEX1 P27695 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2595467 0.81 ALDH1A1 (0.35) PTGER4AXLALDH1A1CYP3A4TSHR
SCHEMBL26921845 0.78 RXFP1 (0.48) ALDH1A1NPC1CA1CA2CA9
SCHEMBL441345 0.77 KDM1A (0.43) AXLALDH1A1MEN1MAPTKMT2A
SCHEMBL10992080 0.77 ALDH1A1 (0.39) PTGER4AXLALDH1A1CYP3A4TSHR
SCHEMBL9339526 0.75 HTR2A (0.32) NPC1RAB9AHTR2AHTR2CHTR2B
SCHEMBL10990726 0.75 ALDH1A1 (0.36) PTGER4AXLALDH1A1CYP3A4TSHR
SCHEMBL31387674 0.75 PTGER4 (0.43) PTGER4AXLALDH1A1CYP3A4TSHR
SCHEMBL159338 0.75 TSHR (0.39) ALDH1A1CYP3A4TSHRTDP1ALOX15
SCHEMBL38652629 0.75 AXL (0.34) AXLALDH1A1MEN1MAPTKMT2A
SCHEMBL29435968 0.75 TSHR (0.39) ALDH1A1CYP3A4TSHRTDP1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611797-B1 QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS HANMI SCIENCE CO LTD (KR) 2016-12-28 EP claimed
US-8835458-B2 Quinoline or quinazoline derivatives with apoptosis inducing activity on cells HANMI SCIENCE CO., LTD (KR) 2014-09-16 US claimed
CN-103237801-A Quinoline or quinazoline derivatives having apoptosis-inducing activity on cells HANMI HOLDINGS CO LTD 2013-08-07 CN claimed
EP-2611797-A2 QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS Hanmi Science Co., Ltd. (KR) 2013-07-10 EP claimed
US-20130165386-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS HANMI SCIENCE CO., LTD (KR) 2013-06-27 US claimed
CN-102001913-B Method for synthesizing 2-chloro-3-fluorobromobenzene CHANGZHOU INST ENG TECH 2013-03-13 CN claimed
WO-2012030160-A2 QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS HANMI HOLDINGS CO., LTD. (KR) 2012-03-08 WO claimed
CN-102001913-A Method for synthesizing 2-chloro-3-fluorobromobenzene CHANGZHOU INST ENG TECH 2011-04-06 CN claimed
CN-117024411-B Isoquinoline as HPK1 inhibitor 豪夫迈·罗氏有限公司 2026-05-19 CN disclosed
US-12630542-B2 Compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium ENDOGENA THERAPEUTICS, INC. (US) 2026-05-19 US disclosed
US-20260109709-A1 2-AMINO IMIDAZOLE DERIVATIVES AS PRMT5 INHIBITORS MIRATI THERAPEUTICS INC (US) 2026-04-23 US disclosed
EP-4313981-B1 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS PFIZER (US) 2026-02-25 EP disclosed
EP-3826722-B1 ISOQUINOLINE COMPOUNDS AND USES THEREOF HOFFMANN LA ROCHE (CH) 2026-02-18 EP disclosed
EP-4225739-B1 PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS MERCK SHARP & DOHME LLC (US) 2026-01-21 EP disclosed
WO-2009020234-A2 PYRROLIDIN-2 -ONE DERIVATIVES AS ANDROGEN RECEPTOR MODULATOR TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-02-12 WO disclosed
US-20080318950-A1 Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof HANMI PHARM. CO., LTD (KR) 2008-12-25 US disclosed
CN-101304978-A Quinazoline derivatives as multiplex inhibitors and process for their preparation HANMI PHARM IND CO LTD (KR) 2008-11-12 CN disclosed
EP-1951686-A1 QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF Hanmi Pharm. Co., Ltd. (KR) 2008-08-06 EP disclosed
WO-2008002039-A1 QUINAZOLINE DERIVATIVES FOR INHIBITING THE GROWTH OF CANCER CELL HANMI PHARM. CO., LTD. (KR) 2008-01-03 WO disclosed
WO-2007055514-A1 QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF HANMI PHARM. CO., LTD. (KR) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260109709-A1 2-AMINO IMIDAZOLE DERIVATIVES AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 PTGER4 4796/4885AXL 2729/4885ALDH1A1 4159/4885
US-12630542-B2 Compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium ALDH1A2, NR2E3, GFRA1 PTGER4 267/4885AXL 2938/4885ALDH1A1 375/4885
US-20080318950-A1 Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof ABL1, JAK1, BTK PTGER4 4530/4885AXL 518/4885ALDH1A1 3502/4885
US-20130165386-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS CASP7, API5, BAX PTGER4 4327/4885AXL 4556/4885ALDH1A1 4307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.